Sovateltide (IRL‐1620) prevents oxidative damage, mitochondrial dysfunction, and memory loss in a transgenic mouse model of Alzheimer’s disease

Alzheimer’s disease (AD) is the sixth leading cause of death in the United States and has no treatment or cure. New treatments are urgently needed. We have demonstrated cerebral endothelin B receptors (ETBR) as a potential target to treat AD. However, the mechanism of ETBR‐mediated neural regeneration and repair remains elusive. Therefore, we investigated the effect of sovateltide on progenitor cells mediated neural regeneration and its effect on cerebral tissue repair and functional recovery in transgenic AD mice.